Samsara Vision, which makes medical implants for retinal diseases including AMD, filed on Wednesday with the SEC to raise up to $31 million in an initial public offering.
Samsara Vision is a specialty medical device company focused on the research, development, manufacturing, and marketing proprietary ophthalmic devices and technologies intended for individuals with untreatable retinal disorders, particularly Age-Related Macular Degeneration (AMD). Its current product line consists of its first-generation implantable miniature telescope (IMT), known as WA IMT; its Smaller-Incision, New Generation (SING) IMT; and its Tsert delivery system. WA IMT was approved by the FDA in 2010 and received a CE Mark in 2005. SING IMT received a CE Mark in April 2020, and the company began commercializing its SING IMT in Europe in 2021. In addition, it is in the process of establishing the regulatory pathway into the US.
The Far Hills, NJ-based company was founded in 2015 and plans to list on the Nasdaq under the symbol SMSA. Samsara Vision filed confidentially on October 9, 2020. ThinkEquity is the sole bookrunner on the deal. No pricing terms were disclosed.
